Sequential tyrosine kinase inhibitor therapy for EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient: a 24-month case report
To our knowledge, this is the first reported case of an EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient benefiting from sequential multi-TKI therapy. This case underscores the importance of vigilant cancer surveillance in transplant recipients and suggests that individualized TKI sequencing may offer clinical benefit, although further evidence is required.
Authors
- Baoquan Lin (ORCID: https://orcid.org/0000-0002-1780-2451)
- Wenxiu Xie (ORCID: https://orcid.org/0000-0002-8528-5193)
- Feng Chen (ORCID: https://orcid.org/0009-0000-4166-0847)
- Wei Liu (ORCID: https://orcid.org/0000-0002-9302-8170)
- Zongyang Yu
- Jia Ye (ORCID: https://orcid.org/0000-0002-7242-6065)
- Lei Gu (ORCID: https://orcid.org/0000-0002-3254-9167)
- Lei Zhang (ORCID: https://orcid.org/0000-0003-1901-3752)
Institutions
- Fujian University of Traditional Chinese Medicine (CN)
- Fujian Medical University (CN)
- Longyan University (CN)
- Soochow University (CN)
- 174th hospital of the People's Liberation Army (CN)
- Suzhou Research Institute (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-10-08
- DOI
- https://doi.org/10.3389/fmed.2025.1651584
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province